The infiltration of diverse immune cell types within the DLBCL microenvironment contributes significantly to disease heterogeneity, with the composition and abundance of these cells correlating with clinical outcomes.Mast cell infiltration has been identified as a favorable prognostic marker, while higher levels of CD8+ and CD4+ T cells predict better survival in DLBCL (Kusano et al., 2017; Qi et al., 2022). The gene discussed is CD4; the disease is diffuse large B-cell lymphoma.